---
title: "Sonoma Pharmaceuticals Cancels Adjourned Special Stockholder Meeting"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296409897.md"
description: "Sonoma Pharmaceuticals (SNOA) cancelled its adjourned special stockholder meeting on August 19, 2026, due to failure to reach the required quorum of one-third of outstanding shares. Consequently, proposed measures will not proceed, leaving governance and capital structure unchanged. The company also decided against seeking additional proxies. TipRanks' AI analyst rates SNOA as Neutral, citing weak financial quality despite revenue growth."
datetime: "2026-08-19T21:48:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296409897.md)
  - [en](https://longbridge.com/en/news/296409897.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296409897.md)
generator: "portal-rs"
---

# Sonoma Pharmaceuticals Cancels Adjourned Special Stockholder Meeting

Sonoma Pharmaceuticals ( (SNOA) ) has shared an announcement.

On August 19, 2026, Sonoma Pharmaceuticals, Inc. convened an adjourned special meeting of stockholders that had been called pursuant to a proxy process initiated in early May 2026. The meeting covered 3,473,554 eligible common shares, but a quorum of one-third of the outstanding shares, or 1,157,852 shares, was required to conduct business.

Because the required quorum was not reached, the chairman formally cancelled the special meeting and the company decided not to seek additional proxies from shareholders. The cancellation indicates that whatever proposals were to be considered at the meeting will not move forward at this time, leaving the company’s existing governance and capital structure unchanged for stakeholders.

**Spark’s Take on SNOA Stock**

According to Spark, TipRanks’ AI Analyst, SNOA is a Neutral.

The score is held down primarily by weak financial quality—ongoing losses and negative, worsening free cash flow—despite revenue growth and stable gross margins. Technicals are modestly supportive in the short term (positive MACD; price above 20/50-day averages) but remain below longer-term averages, and valuation is constrained by negative earnings (negative P/E) with no dividend support.

To see Spark’s full report on SNOA stock,  
 click here. 

**More about Sonoma Pharmaceuticals**

Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing medical products, with its common stock widely held by public investors. The company’s governance and capital structure decisions are subject to shareholder approval at special and annual meetings, reflecting typical practices in the U.S. public markets.

**Average Trading Volume:** 169,160

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** $6.32M

### Related Stocks

- [SNOA.US](https://longbridge.com/en/quote/SNOA.US.md)

## Related News & Research

- [ANI Pharma CEO Nikhil Lalwani disposes of 5,400 common shares worth $401,220](https://longbridge.com/en/news/297093829.md)
- [Ligand targets $150-$250 million in annual investments as royalty revenue tops $225 million in 2026 guidance](https://longbridge.com/en/news/297061481.md)
- [LGND: XOMA acquisition doubled the portfolio and set the stage for accelerated, diversified growth](https://longbridge.com/en/news/297069508.md)
- [Artelo Biosciences announces 1-for-9 reverse stock split effective Aug. 31](https://longbridge.com/en/news/297181623.md)
- [Dr. Reddy’s Laboratories Allots New Shares Under Employee Stock Option Scheme](https://longbridge.com/en/news/297077947.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**